TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18976472
Drug: Immediate-release hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release hydromorphone
Study: 18976472
Drug: Sustained-release hydromorphone
Normalized name: hydromorphone Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release hydromorphone
Study: 18976849
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) doses greater than 0.4 mg/kg/d
Study: 18976849
Drug: Amiloride (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (5 mg/d) alone
Study: 18977647
Drug: T-SPOT.TB assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-SPOT.TB assay at T0 (initial treatment)
Study: 18977647
Drug: T-SPOT.TB assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-SPOT.TB assay at TE (end of treatment)
Study: 18977647
Drug: T-SPOT.TB assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-SPOT.TB assay at TE+6 (6 months after treatment)
Study: 18978345
Drug: Periocular topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocular topotecan (0.5 mg starting dose, escalated to 2 mg max dose)
Study: 18983669
Drug: New short
Approvals — FDA: no, EMA: no, PMDA: no
Description: New short uncemented, proximally fixed anatomic femoral implant
Study: 18986547
Drug: Final survey
Approvals — FDA: no, EMA: no, PMDA: no
Description: Final survey administered to the study population
Study: 19001517
Drug: Overall SSA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall SSA treatment
Study: 19005970
Drug: Supplemental vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental vitamin C (358.0 mg/day)
Study: 19014833
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg/d (with option to increase to 10 mg at weeks 4 and 8)
Study: 19015393
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m² per day for 5 days for 6 cycles) and Rituximab (375 mg/m² per week for 8 infusions)
Study: 19020749
Drug: Cetuximab (anti-EGFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (anti-EGFR antibody)
Study: 19020749
Drug: Cetuximab +
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab + CDDP (optimal doses)
Study: 19032103
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level nucleoside reverse-transcriptase inhibitor-resistant HIV
Study: 19033011
Drug: Late abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late abciximab (LA group: periprocedural administration of abciximab in the cathlab)
Study: 19038036
Drug: Six-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Six-dose regimen of artemether-lumefantrine (AL) tablets
Study: 19040767
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored programmes based on participants' individual assessment of their most important daily activities, implemented over 12 weeks and 24 weeks.
Study: 19040767
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care and treatment provided to the control group.
Study: 19047220
Drug: Diphtheria, tetanus,
Normalized name: Diphtheria, Tetanus, Poliomyelitis adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine
Study: 19047220
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diphtheria, tetanus, acellular pertussis vaccine and separate doses of hepatitis B and inactivated poliovirus vaccines)
Study: 19054318
Drug: XIIaA in
Approvals — FDA: no, EMA: no, PMDA: no
Description: XIIaA in patients with admission TnT <= 0.05 ng mL(-1)
Study: 19058002
Drug: Furazolidone 200
Normalized name: furazolidone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furazolidone 200 mg b.i.d, co-amoxiclav 1 g b.i.d., colloidal bismuth subcitrate 240 mg b.i.d., and esomeprazole 40 mg b.i.d. for 14 days
Study: 19058002
Drug: Classical triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical triple therapy (not specified in detail)
Study: 19064724
Drug: VAD-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAD-based induction chemotherapy followed by nonmyeloablative total body irradiation and allografting from an HLA-identical sibling
Study: 19067714
Drug: UVB treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: UVB treatments (6 to 9 sessions, 2 to 3 times weekly)
Study: 19067714
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated vitiliginous skin)
Study: 19067714
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (untreated normal skin)
Study: 19070891
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy (40-46 Gy in 20-25 daily fractions, treating five times a week)
Study: 19075070
Drug: Caspofungin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin at 25 mg/m(2) once daily as a 1-hour infusion
Study: 19076979
Drug: SR29142 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR29142 at 0.15 mg/kg per day
Study: 19076979
Drug: SR29142 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR29142 at 0.20 mg/kg per day
Study: 19077198
Drug: Screening and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening and treatment of chlamydial infection via vaginal swabs tested by PCR, with treatment for those infected.
Study: 19077198
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with vaginal swabs stored and analyzed after a year, without immediate treatment.
Study: 19087147
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment for degenerative cervical radiculopathy, specific modalities not detailed, duration not specified.
Study: 19087222
Drug: NT-proBNP >300
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP >300 pg/ml
Study: 19087222
Drug: D-dimer >2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer >2000 ng/ml
Study: 19087222
Drug: H-FABP >6
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-FABP >6 ng/ml
Study: 19087222
Drug: cTnI >0.09
Approvals — FDA: no, EMA: no, PMDA: no
Description: cTnI >0.09 ng/ml
Study: 19087222
Drug: myoglobin >70
Approvals — FDA: no, EMA: no, PMDA: no
Description: myoglobin >70 ng/ml
Study: 19092346
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with gemcitabine (1000 mg/m²) and cisplatin (50 mg/m²) for 4 bi-weekly cycles
Study: 19094074
Drug: Lanreotide Autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide Autogel (ATG) 120 mg
Study: 19096013
Drug: R406, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: R406, an inhibitor of Syk function, starting at 75 mg and escalating to 175 mg twice daily
Study: 19096013
Drug: R406, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: R406, an inhibitor of Syk function
Study: 19103636
Drug: Rituximab (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1000 mg infusion at baseline and day 15, with 100 mg methylprednisolone at each infusion)
Study: 19106083
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy with ABCB1 TT genotype (two variant alleles at nucleotide 3435)
Study: 19106083
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy with CYP2C19 loss-of-function alleles (*2, *3, *4, or *5)
Study: 19106083
Drug: Clopidogrel therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel therapy with CYP2C19 loss-of-function alleles among patients undergoing percutaneous coronary intervention
Study: 19109557
Drug: Tipifarnib (300-600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (300-600 mg twice daily for 14 or 21 days) plus etoposide (100-200 mg daily on days 1-3 and 8-10)
Study: 19109557
Drug: Tipifarnib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (600 mg) plus etoposide (100 mg)
Study: 19109557
Drug: Tipifarnib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (400 mg) plus etoposide (200 mg)
Study: 19114680
Drug: Caspofungin at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin at 50 mg/m(2) once daily for 2 to 21 days (mean, 9.3 days)
Study: 19117345
Drug: Imatinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib dose escalation to 600 mg or 800 mg daily
Study: 19117345
Drug: Imatinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib dose escalation based on protocol criteria
Study: 19117345
Drug: Imatinib dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib dose escalation based on ELN recommendations
Study: 19118066
Drug: HPV16 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 DNA vaccine (3 mg)
Study: 19118066
Drug: HPV16 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 DNA vaccine (0.5 mg and 1 mg)
Study: 19118066
Drug: HPV16 DNA
Normalized name: TOXOPLASMA GONDII DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16 DNA vaccine
Study: 19119321
Drug: Six-week extended-dose
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-week extended-dose nevirapine (SWEN)
Study: 19141590
Drug: Once-weekly bisphosphonates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly bisphosphonates
Study: 19142112
Drug: Aripiprazole combined
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole combined with escitalopram (maximum dosages of 20 mg/d for escitalopram and 30 mg/d for aripiprazole)
Study: 19144941
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (180 microg per week) and ribavirin (1000 or 1200 mg per day) for 48 weeks
Study: 19144941
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a and ribavirin treatment
Study: 19153124
Drug: Tipifarnib-fulvestrant combination
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tipifarnib-fulvestrant combination (fulvestrant 250 mg i.m. on day 1 plus tipifarnib 300 mg orally twice daily on days 1-21 every 28 days)
Study: 19153124
Drug: Tipifarnib-fulvestrant combination
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tipifarnib-fulvestrant combination
Study: 19153830
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy in women with intermediate CYP2D6 metabolizer status
Study: 19153830
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy in women with poor CYP2D6 metabolizer status
Study: 19153830
Drug: Tamoxifen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen therapy in women with extensive CYP2D6 metabolizer status
Study: 19154581
Drug: Involvement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Involvement of a physician or medical professional in providing therapy
Study: 19155249
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate variability measures (e.g., very-low frequency component <5.7 ln ms(2))
Study: 19165956
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of incidental intracranial aneurysms
Study: 26359024
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin detemir (IDet)
Study: 19167685
Drug: Plerixafor (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plerixafor (240 microg/kg/day) combined with G-CSF (10 microg/kg/day) for up to 9 days, starting plerixafor on day 4.
Study: 19167685
Drug: Plerixafor and
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor and G-CSF combination treatment.
Study: 19167838
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg intravenous) every 2 weeks of 28-day cycles until tumor progression; 30 Gy of hypofractionated stereotactic radiotherapy (HFSRT) in five fractions after the first cycle of bevacizumab.
Study: 19170709
Drug: Cushing syndrome
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cushing syndrome (CS) treatment
Study: 19171730
Drug: Gabapentin extended
Normalized name: gabapentin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin extended release, dosage and duration not available
Study: 19175499
Drug: Dalteparin injected
Normalized name: dalteparin Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin injected s.c. once daily at a prophylactic dose.
Study: 19181369
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NAC) with paclitaxel and carboplatin, 4 cycles before interval debulking surgery (IDS) and 4 additional cycles after surgery.
Study: 19181452
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment for 6 months
Study: 19181644
Drug: IL-1 receptor
Normalized name: IL-1 TRAP
DrugBank: Rilonacept (DB06372)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IL-1 receptor antagonist (IL-1Ra) + low-dose dexamethasone (20 mg/wk)
Study: 19182205
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg on days 1-21), Adriamycin (9 mg/m² intravenously on days 1-4), Dexamethasone (40 mg on days 1-4 and 17-20) with pegfilgrastim
Study: 19191590
Drug: NRTI discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRTI discontinuation
Study: 19191652
Drug: Vicriviroc (CCR5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicriviroc (CCR5 antagonist)
Study: 19193344
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg/day for 8 weeks
Study: 19204798
Drug: EPOCH chemotherapy
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPOCH chemotherapy (etoposide, doxorubicin, vincristine, daily prednisone, bolus cyclophosphamide) followed by antiretroviral therapy (daily zidovudine, lamivudine, and alpha interferon-2a for up to one year)
Study: 19210163
Drug: 1 or
Normalized name: G-1 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 doses of H9N2 LAIV A/chicken/Hong Kong/G9/97 (10^7-TCID(50) administered intranasally)
Study: 19210946
Drug: Complex polypharmacy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex polypharmacy (use of 4 or more medications)
Study: 19217176
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 to 80 mg
Study: 19218820
Drug: Intravenous gammaglobulin
Normalized name: Human gammaglobulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous gammaglobulin (IgIV) administered monthly for 12 months
Study: 19220909
Drug: Adapted standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted standard behavioral treatment (SBT)
Study: 19221274
Drug: Topical regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regimen of 5-fluorouracil, 0.5%, cream
Study: 19228281
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after recurrent VTE exclusion
Study: 19237390
Drug: Salmeterol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol monotherapy for 2 weeks
Study: 19237390
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with salmeterol and fluticasone for 2 weeks
Study: 19237390
Drug: Salmeterol monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol monotherapy
Study: 19237390
Drug: Beta(2)-receptor polymorphisms
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta(2)-receptor polymorphisms
Study: 19245964
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) defined by Fasting Insulin Resistance Index (FIRI) > or = 2.7
Study: 19245964
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) defined by FIRI > or = 2.7
Study: 19254204
Drug: Subcutaneous (SC)
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) epoetin beta
Study: 19254204
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) epoetin beta
Study: 19255017
Drug: Caspofungin 70
Normalized name: caspofungin 70 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin 70 mg/m(2) on day 1, followed by 50 mg/m(2) per day (maximum: 70 mg/day) for 2 to 87 days
Study: 19257800
Drug: Aliskiren/amlodipine 300/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine 300/10 mg (in stage 2 hypertension subgroup)
Study: 19257800
Drug: Aliskiren/amlodipine 150/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren/amlodipine 150/5 mg
Study: 19262209
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg and Pioglitazone 30 mg daily for 6 months
Study: 19265494
Drug: Fosbretabulin 45
Normalized name: Fosbretabulin
DrugBank: Fosbretabulin (DB12577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosbretabulin 45 mg/m² as a 10-minute intravenous infusion on days 1, 8, and 15 of a 28-day cycle
Study: 19265494
Drug: Fosbretabulin 45
Normalized name: Fosbretabulin
DrugBank: Fosbretabulin (DB12577)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosbretabulin 45 mg/m²
Study: 19267708
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g TTA daily for 28 days
Study: 19270751
Drug: Fludarabine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (25 mg/m²/day for 5 days)
Study: 19277125
Drug: 5-MTHF and
Normalized name: (6S)-5-MTHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-MTHF and vitamin B12 supplementation (7.5 mg/day of 5-MTHF and 0.5 mg/day of vitamin B12) for 24 weeks
Study: 19277602
Drug: lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: lifestyle modification plus pioglitazone, 30 mg (n = 204)
Study: 19282789
Drug: Isolated limb
Normalized name: ISOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isolated limb infusion (ILI) with melphalan and dactinomycin
Study: 19284416
Drug: Depletion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depletion of L-ascorbic acid (LAA) through a diet deficient in LAA
Study: 19284416
Drug: Supplementation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementation of L-ascorbic acid (LAA) via daily intravenous administration
Study: 19286847
Drug: Febuxostat (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (both doses)
Study: 19293071
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 to 162 mg/d
Study: 19293071
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg or greater
Study: 19293071
Drug: Aspirin greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin greater than 100 mg
Study: 19293071
Drug: Aspirin greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin greater than 100 mg with clopidogrel
Study: 19293071
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 to 81 mg
Study: 19297054
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir therapy
Study: 19301723
Drug: Non-mobilized peripheral
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-mobilized peripheral blood angiogenic cell precursors (NMPB-ACPs) therapy
Study: 19307014
Drug: Weekly topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly topotecan 3.5 mg/m(2) and docetaxel 30 mg/m(2) for 3 consecutive weeks, repeated every 4 weeks for 6 cycles or until disease progression, unacceptable toxicity, or death.
Study: 19317960
Drug: fMRI-guided rTMS
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fMRI-guided rTMS treatment, details on dosage and duration not available
Study: 19323966
Drug: Varenicline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (0.5 mg daily titrated to 1 mg twice daily)
Study: 19336742
Drug: Bortezomib (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.5 mg/m² on days 1, 4, 8, and 11, every 21 days)
Study: 19339913
Drug: MTRR 66A>G
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTRR 66A>G genotype (MTRR 66AA, AG, GG)
Study: 19341509
Drug: Citalopram up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram up to 60 mg/d for up to 14 weeks
Study: 19348029
Drug: Fesoterodine 4
Normalized name: fesoterodine 4 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine 4 mg once daily for 4 weeks, with possible escalation to 8 mg based on efficacy and tolerability assessment.
Study: 19348029
Drug: Fesoterodine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fesoterodine treatment satisfaction at week 12.